Network-Level Effects of Nitrous Oxide in the Human Brain
Status: | Enrolling by invitation |
---|---|
Conditions: | Healthy Studies |
Therapuetic Areas: | Other |
Healthy: | No |
Age Range: | 21 - 40 |
Updated: | 2/17/2019 |
Start Date: | July 21, 2017 |
End Date: | December 31, 2020 |
The purpose of this study is to understand how a commonly used drug, nitrous oxide, acts on
the brain to reduce pain. Nitrous oxide is commonly used in anesthesiology but there is
limited knowledge on how this drug affects functional networks in the brain.
the brain to reduce pain. Nitrous oxide is commonly used in anesthesiology but there is
limited knowledge on how this drug affects functional networks in the brain.
The objective of this study is to identify the network transformations that account for the
analgesic effects of nitrous oxide. Our hypothesis is that analgesic doses of nitrous oxide
increase network efficiency and disrupt normal pain processingOur approach is to administer
subanesthetic nitrous oxide during the acquisition of fMRI (functional magnetic resonance
imaging) and EEG (electroencephalogram).
analgesic effects of nitrous oxide. Our hypothesis is that analgesic doses of nitrous oxide
increase network efficiency and disrupt normal pain processingOur approach is to administer
subanesthetic nitrous oxide during the acquisition of fMRI (functional magnetic resonance
imaging) and EEG (electroencephalogram).
Inclusion Criteria:
1. Body mass index <30
2. Must be right-handed
3. Must be capable of giving written informed consent
Exclusion Criteria:
1. History of obstructive sleep apnea;
2. History of a difficult airway with a previous anesthetic
3. Gastroesophageal reflux;
4. Hypertension or other cardiovascular abnormalities;
5. Pulmonary hypertension;
6. History of recreational drug use;
7. History of chronic alcohol abuse
8. Having any chronic medical illness involving pain;
9. History of major depression;
10. History of psychosis or bipolar disorder;
11. History of methylenetetrahydrofolate reductase deficiency;
12. History of a known hypersensitivity to ketamine, midazolam, Zofran, labetalol or
glycopyrrolate
13. History of seizures or other neurologic disorders;
14. Pregnant or nursing mothers;
15. Tattoos on the head or neck region - all other tattoos are subject to determination by
investigators;
16. Contraindications to neuroimaging methods;
17. Any impairment, activity or situation that in the judgment of the Study Coordinator or
Principal Investigators would prevent satisfactory completion of the study protocol.
We found this trial at
1
site
Click here to add this to my saved trials